The Global Janus Kinase Inhibitor Market Continues To Grow Owing To the Increased Demand from Healthcare Organizations to Treat Conditions Such As SLE and Increasing Investment in the R&D Sector
Janus Kinase Inhibitor is one of the most promising newly-developed anti-neurotransmitter drugs that is developed for treating diseases that involve the neuroendocrine system, the pituitary gland, and other glands and organ systems. The drug specifically affects the production of neuropeptide Y, a chemical neurotransmitter in the brain that is involved in regulating mood, anxiety, and sexuality. Janus Kinase Inhibitor works by inhibiting the action of one or perhaps more of the family of neurotransmitters, thereby interfering with the neurotransmitter signaling pathway. Neurotransmitters are chemical messages sent from one nerve cell to another, which typically include dopamine, epinephrine, norepinephrine, and serotonin. When these neurotransmitters are broken down by Janus Kinase Inhibitor, the brain does not receive the neurotransmitter message that it normally needs for normal functioning. This is believed to underlie the depression, anxiety, and mood disorders that many of...